Preexisting Heterotypic Ligand-blocking Antibody Does Not Protect Against Genogroup II Norovirus Episodes in Young Children
Authors
Becker-Dreps S, Brewer-Jensen PD, González F, Reyes Y, Mallory ML, Gutiérrez L, Vielot NA, Diez-Valcarce M, Vinjé J, Baric RS, Lindesmith LC, Bucardo F.
Abstract
A birth cohort design was used to understand whether heterotypic ligand-blocking norovirus antibodies provide cross-protection within the GII genogroup. We found that almost one-half of children who experienced a norovirus GII episode had preexisting antibodies heterotypic to the infecting genotype; therefore, these antibodies did not provide cross-protection.
Citation
Becker-Dreps S, Brewer-Jensen PD, González F, Reyes Y, Mallory ML, Gutiérrez L, Vielot NA, Diez-Valcarce M, Vinjé J, Baric RS, Lindesmith LC, Bucardo F. Preexisting Heterotypic Ligand-blocking Antibody Does Not Protect Against Genogroup II Norovirus Episodes in Young Children. J Pediatric Infect Dis Soc. 2022 Oct 25;11(10):459-462. doi: 10.1093/jpids/piac063. PMID: 35849117; PMCID: PMC9595053.
Publication Link